Press release
The Future of Refractory Multiple Myeloma Therapy: 75+ Companies Advancing the Clinical Pipeline | Rapa Therapeutics, Novartis, AbbVie, MiNK Therapeutics, AbbVie, Amgen
Refractory Multiple Myeloma Pipeline
DelveInsight's 'Refractory Multiple Myeloma Pipeline Insight 2024' report provides comprehensive global coverage of pipeline Refractory Multiple Myeloma therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Refractory Multiple Myeloma pipeline domain.
For Refractory Multiple Myeloma emerging drugs, the Refractory Multiple Myeloma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Refractory Multiple Myeloma Pipeline Report
• DelveInsight's Refractory Multiple Myeloma Pipeline analysis depicts a robust space with 75+ active players working to develop 80+ pipeline drugs for Refractory Multiple Myeloma treatment.
• The leading Refractory Multiple Myeloma companies include MorphoSys, Janssen Research & Development, LLC, Rapa Therapeutics, Novartis, AbbVie, MiNK Therapeutics, AbbVie, Amgen, Gracell Biopharmaceuticals, Inc., Zhejiang ACEA Pharmaceutical Co. Ltd., Allogene Therapeutics, Beijing InnoCare Pharma Tech Co., Ltd., Takeda, Novartis Pharmaceuticals, and others are evaluating their lead assets to improve the Refractory Multiple Myeloma treatment landscape.
• Key Refractory Multiple Myeloma pipeline therapies in various stages of development include Felzartamab, Talquetamab, RAPA-201, PHE885, ABBV 453, AGENT 797, Venetoclax, Dexamethasone, GC012F, STI-6129, ABT-199, ALLO-605, ICP-490, TAK-981, AUY922, and others.
• In February 2025, Opna Bio announced that its oral small molecule inhibitor, OPN-6602, received FDA Orphan Drug designation for multiple myeloma. OPN-6602 targets E1A-binding protein (EP300) and CREB-binding protein (CBP).
• In December 2024, Bristol Myers Squibb and 2seventy bio, Inc. announced that the U.S. Food and Drug Administration (FDA) approved Abecma® (idecabtagene vicleucel; ide-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma.
• In Nov 2024, Nanjing Leads Biolabs Co., Ltd. announced that LBL-034, a humanized bispecific T-cell engaging antibody targeting GPRC5D and CD3 for multiple myeloma, has received Orphan Drug Designation (ODD) from the FDA.
• In Sept 2024, Sanofi's SARCLISA (isatuximab) gotapproved by the FDA as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant.
Request a sample and discover the recent breakthroughs happening in the Refractory Multiple Myeloma pipeline landscape @ https://www.delveinsight.com/report-store/refractory-multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Refractory Multiple Myeloma Overview
Multiple myeloma is a type of cancer that originates in plasma cells, a type of white blood cell. Although it is considered rare, accounting for less than 2% of cancers, it is the most common form of plasma cell tumor, as stated by the CDC.
Multiple myeloma is classified as refractory when it does not respond to treatment or stops responding during treatment. In patients with refractory multiple myeloma, symptoms that were initially present before treatment may return, or new symptoms may develop. These symptoms are typically the same as those of multiple myeloma and may either persist or recur after treatment.
The most common symptom of multiple myeloma, including refractory multiple myeloma, is bone pain. This occurs because abnormal plasma cells multiply in the bone marrow, the soft tissue inside bones responsible for producing new blood cells.
Experts are still uncertain about the exact cause of multiple myeloma. However, it is believed that gene changes may play a role in making the cancer more resistant to treatment, which could explain why some cases of multiple myeloma become refractory.
Find out more about Refractory Multiple Myeloma medication @ https://www.delveinsight.com/report-store/refractory-multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Refractory Multiple Myeloma Treatment Analysis: Drug Profile
Felzartamab: MorphoSys
Felzartamab is an investigational human monoclonal antibody developed using MorphoSys' HuCAL® antibody technology. The antibody targets against CD38 present on the surface of multiple myeloma cells. The drug candidate uses antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) for tumor cell killing. Currently it is in Phase III stage of clinical trial evaluation to treat Refractory Multiple Myeloma.
RAPA-201: Rapa Therapeutics
RAPA-201 It is a type of autologous cell therapy. The drug candidate is gene transference, T lymphocyte replacements and work on the same mechanism of action. Currently the drug is being evaluated in Phase II for the treatment of Refractory Multiple Myeloma.
PHE885: Novartis
PHE885 is an autologous, fully human, BCMA-directed CAR T-cell therapy being developed by Novartis for the treatment of refractory multiple myeloma. It is administered through intravenous route. The therapeutic candidate consists of autologous T cells that are genetically modified to express chimeric antigen receptor that targets BCMA (B-cell maturation antigen). Currently it is in Phase II stage of clinical trials.
Key Refractory Multiple Myeloma Therapies and Companies
• Felzartamab : MorphoSys
• Talquetamab : Janssen Research & Development, LLC
• RAPA-201 : Rapa Therapeutics
• PHE885 : Novartis Pharmaceuticals
• ABBV 453 : AbbVie
• AGENT 797 : MiNK Therapeutics
• Venetoclax : AbbVie and Roche
• GC012F : Gracell Biopharmaceuticals, Inc.
• STI-6129 : Sorrento Therapeutics
• ABT-199 : AbbVie
• ALLO-605 : Allogene Therapeutics
• ICP-490 : InnoCare
• TAK-981 : Takeda
• AUY922 : Vernalis
Learn more about the novel and emerging Refractory Multiple Myeloma pipeline therapies @ https://www.delveinsight.com/report-store/refractory-multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Refractory Multiple Myeloma Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.
By Stage
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
By Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
By Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Scope of the Refractory Multiple Myeloma Pipeline Report
• Coverage: Global
• Key Refractory Multiple Myeloma Companies: MorphoSys, Janssen Research & Development, LLC, Rapa Therapeutics, Novartis, AbbVie, MiNK Therapeutics, AbbVie, Amgen, Gracell Biopharmaceuticals, Inc., Zhejiang ACEA Pharmaceutical Co. Ltd., Allogene Therapeutics, Beijing InnoCare Pharma Tech Co., Ltd., Takeda, Novartis Pharmaceuticals, and others.
• Key Refractory Multiple Myeloma Pipeline Therapies: Felzartamab, Talquetamab, RAPA-201, PHE885, ABBV 453, AGENT 797, Venetoclax, Dexamethasone, GC012F, STI-6129, ABT-199, ALLO-605, ICP-490, TAK-981, AUY922, and others.
Dive deep into rich insights for drugs used for Refractory Multiple Myeloma treatment; visit @ https://www.delveinsight.com/report-store/refractory-multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Table of Contents
1. Introduction
2. Executive Summary
3. Refractory Multiple Myeloma Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Refractory Multiple Myeloma Pipeline Therapeutics
6. Refractory Multiple Myeloma Pipeline: Late-Stage Products (Phase III)
7. Refractory Multiple Myeloma Pipeline: Late-Stage Products (Phase III)
8. Refractory Multiple Myeloma Pipeline: Mid-Stage Products (Phase II)
9. Refractory Multiple Myeloma Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix
Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release The Future of Refractory Multiple Myeloma Therapy: 75+ Companies Advancing the Clinical Pipeline | Rapa Therapeutics, Novartis, AbbVie, MiNK Therapeutics, AbbVie, Amgen here
News-ID: 3899886 • Views: …
More Releases from DelveIinsight Business Research
Thymidine Kinase 2 Deficiency Market Insights: Unmet Needs and Emerging Therapie …
The Thymidine Kinase 2 deficiency (TK2d) market is poised for substantial growth in the coming decade, fueled by increasing awareness of this rare genetic disorder and the development of promising therapies like MT1621 (UCB).
DelveInsight's "Thymidine Kinase 2 Deficiency Market Insight, Epidemiology and Market Forecast - 2034" report delivers comprehensive insights into the current TK2d landscape and future market trends across the 7MM (United States, EU4, the United Kingdom, and Japan).…
Pigment Epithelial Detachment Market Outlook: Aging Population, AI-Driven Diagno …
Recent analysis by DelveInsight indicates that the retinal pigment epithelium market is poised for notable growth, with the 7MM expected to achieve a respectable CAGR. This growth is being fueled by several factors, including an aging population, advancements in AI-driven diagnosis, industry collaborations, and novel therapeutic options. Key retinal pigment epithelium companies include Sumitomo Pharma, Healios K.K., Eyestem Research, Luxa Biotechnology, Regenerative Patch Technologies, Lineage Cell Therapeutics, Katairo GmbH, Visgenx…
Chronic Obstructive Pulmonary Disease Market Forecast 2024-2034: Competitive Int …
The chronic obstructive pulmonary disease (COPD) market is projected to experience steady growth in the coming years, driven primarily by increasing diagnosed prevalent cases and the introduction of novel biologics and combination therapies by key COPD companies, including Sanofi, Regeneron Pharmaceuticals, GlaxoSmithKline, AstraZeneca, and Amgen, among others. This market expansion reflects advancements in targeted therapeutic approaches, particularly for patients with specific phenotypes, improved diagnostic capabilities, and rising awareness among healthcare…
Blastic Plasmacytoid Dendritic Cell Neoplasm Treatment Landscape Transforms with …
The Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) market across the 7MM is poised for significant growth through 2034. This growth is driven by advancements in targeted therapies, increased awareness of the disease among healthcare professionals, and ongoing research and development efforts. Major pharmaceutical and biotech companies, including AbbVie, ImmunoGen, Mustang Bio, Genentech, Stemline Therapeutics, Jazz Pharmaceuticals, Menarini Group, Cellex Patient Treatment GmbH, and Xencor, are actively engaged in the BPDCN…
More Releases for Multiple
Mango AI's Multiple Face Swap Video Tool Changes Multiple Faces Instantly
In today's digital world, creating eye-catching and unique content is essential for standing out. The ability to swap multiple faces in a single video opens up creative possibilities, whether for personalized content, comedy or parody videos, or engaging social media posts. Mango AI, developed by Mango Animate, is excited to announce the launch of its advanced multiple face swap video (https://mangoanimate.com/ai/multiple-face-swap-video) tool, which is designed to simplify the creation of…
Multiple Sclerosis Drugs Market
Global Multiple Sclerosis Drugs Market Size research report offers in-depth assessment of revenue growth, market definition, segmentation, industry potential, influential trends for understanding the future outlook and current prospects for the market.
Get a Sample Copy of the Report at - https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/100386
Multiple Sclerosis (MS) is an immune-mediated disease affecting the central nervous system. It is characterized by demyelination, inflammation, degenerative changes such as progressive brain and spinal cord atrophy and neuroaxonal…
Massive Multiple Input Multiple Output (MIMO) Market May Set New Growth Story
A Latest intelligence report published by MR Forecast with title "Global Massive Multiple Input Multiple Output (MIMO) Market Outlook to 2032. A detailed study accumulated to offer Latest insights about acute features of the Massive Multiple Input Multiple Output (MIMO) market. This report provides a detailed overview of key factors in the Global Massive Multiple Input Multiple Output (MIMO) Market and factors such as driver, restraint, past and current trends,…
Multiple Sclerosis Drugs Market - Progressing Towards a Cure: Advancing Multiple …
Newark, New Castle, USA: The "Multiple Sclerosis Drugs Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Multiple Sclerosis Drugs Market: https://www.growthplusreports.com/report/multiple-sclerosis-drugs-market/7983
This latest report researches the industry structure,…
Multiple Sclerosis Drugs Market - Empowering Resilience, Embracing Possibilities …
Newark, New Castle, USA - new report, titled Multiple Sclerosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Multiple Sclerosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Multiple Sclerosis Drugs market. The report offers an overview of…
Massive MIMO (Multiple-input multiple-output) Market 2022-2028 | Detailed Report
The market report delivers an all-inclusive analysis of the market structure along with a forecast of the various segments and sub-segments of the Massive MIMO (Multiple-input multiple-output) industry. This wide-ranging market research report acts as a backbone for the success of business in any niche. The Massive MIMO (Multiple-input multiple-output) market survey report has been prepared by conducting market research in a systematic manner. Moreover, the Massive MIMO (Multiple-input multiple-output)…
